Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma

C. Grandclément, C. Estoppey, E. Dheilly, M. Panagopoulou, T. Monney, C. Dreyfus, J. Loyau, V. Labanca, A. Drake, S. Angelis, A. Rubod, J. Frei, L. N. Caro, S. Blein, E. Martini, M. Chimen, T. Matthes, Z. Kaya, C. M. Edwards, J. R. Edwards, E. Menoret, C. Kervoelen, C. Pellat-Deceunynck, P. Moreau, M. L. Mbow, A. Srivastava, M. R. Dyson, E. A. Zhukovsky, M. Perro () and S. Sammicheli ()
Additional contact information
C. Grandclément: Ichnos Glenmark Innovation
C. Estoppey: Ichnos Glenmark Innovation
E. Dheilly: Ichnos Glenmark Innovation
M. Panagopoulou: Ichnos Glenmark Innovation
T. Monney: Ichnos Glenmark Innovation
C. Dreyfus: Ichnos Glenmark Innovation
J. Loyau: Ichnos Glenmark Innovation
V. Labanca: Ichnos Glenmark Innovation
A. Drake: Ichnos Glenmark Innovation
S. Angelis: Ichnos Glenmark Innovation
A. Rubod: Ichnos Glenmark Innovation
J. Frei: Ichnos Glenmark Innovation
L. N. Caro: Ichnos Glenmark Innovation
S. Blein: Ichnos Glenmark Innovation
E. Martini: Ichnos Glenmark Innovation
M. Chimen: Ichnos Glenmark Innovation
T. Matthes: University Hospital Geneva
Z. Kaya: Botnar Institute, University of Oxford
C. M. Edwards: Botnar Institute, University of Oxford
J. R. Edwards: Botnar Institute, University of Oxford
E. Menoret: Nantes Université, Inserm, CNRS, Université d’Angers
C. Kervoelen: Nantes Université, Inserm, CNRS, Université d’Angers
C. Pellat-Deceunynck: Nantes Université, Inserm, CNRS, Université d’Angers
P. Moreau: Nantes Université, Inserm, CNRS, Université d’Angers
M. L. Mbow: Ichnos Glenmark Innovation
A. Srivastava: Ichnos Glenmark Innovation
M. R. Dyson: Ichnos Glenmark Innovation
E. A. Zhukovsky: Ichnos Glenmark Innovation
M. Perro: Ichnos Glenmark Innovation
S. Sammicheli: Ichnos Glenmark Innovation

Nature Communications, 2024, vol. 15, issue 1, 1-16

Abstract: Abstract Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties. Here we report the development of ISB 1442, a fully human bispecific antibody designed to re-establish synthetic immunity in CD38+ hematological malignancies. ISB 1442 consists of two anti-CD38 arms targeting two distinct epitopes that preferentially drive binding to tumor cells and enable avidity-induced blocking of proximal CD47 receptors on the same cell while preventing on-target off-tumor binding on healthy cells. The Fc portion of ISB 1442 is engineered to enhance complement dependent cytotoxicity, antibody dependent cell cytotoxicity and antibody dependent cell phagocytosis. ISB 1442 thus represents a CD47-BsAb combining biparatopic targeting of a tumor associated antigen with engineered enhancement of antibody effector function to overcome potential resistance mechanisms that hamper treatment of myeloma with monospecific anti-CD38 antibodies. ISB 1442 is currently in a Phase I clinical trial in relapsed refractory multiple myeloma.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-46310-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-46310-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-46310-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().